Kate Bingham BA, MBA

Kate Bingham is one of five Managing Partners serving on the firm’s Investment Committee, which managed seven venture capital funds and one public fund (with greater than $2 billion in total assets) for life sciences investing in the US and Europe. Kate is responsible for biotech investments and activities in the EU and serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. These investments include small-molecule drug discovery and development projects, biotherapeutic development projects, and drug discovery platforms in a broad range of clinical areas.